{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:05:12Z","timestamp":1790013912066,"version":"4.0.1"},"reference-count":186,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003415","name":"Ministarstvo Obrazovanja, Znanosti i Sporta","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006588","name":"Republic of Croatia Ministry of Science and Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFE0115400"],"award-info":[{"award-number":["2022YFE0115400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.bbcan.2023.189052","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T13:07:43Z","timestamp":1702386463000},"page":"189052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models"],"prefix":"10.1016","volume":"1879","author":[{"given":"Vanja","family":"Tadi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Brozovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0095","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0740","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0780","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2023.189052_bb0665","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/annonc\/mds315","article-title":"Optimal first-line treatment in ovarian cancer","volume":"23","author":"Raja","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0525","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0410","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"The dualistic model of ovarian carcinogenesis","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"7353","key":"10.1016\/j.bbcan.2023.189052_bb0345","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Integrated Genomic Analyses of Ovarian Carcinoma","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0395","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PGP.0000000000000725","article-title":"The many uses of p53 immunohistochemistry in gynecological pathology: proceedings of the ISGyP companion society session at the 2020 USCAP Annual9 meeting","volume":"40","author":"K\u00f6bel","year":"2021","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0430","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian Cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189052_bb0505","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3390\/cells8050505","article-title":"Current status of patient-derived ovarian Cancer models","volume":"8","author":"Maru","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0645","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-022-02486-z","article-title":"Harnessing preclinical models for the interrogation of ovarian cancer","volume":"41","author":"Qin","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0440","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2023.189052_bb0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fimmu.2020.00089","article-title":"BRD4 inhibition by AZD5153 promotes antitumor immunity via depolarizing M2 macrophages","volume":"11","author":"Li","year":"2020","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189052_bb0260","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djt007","article-title":"The clinical relevance of Cancer cell lines","volume":"105","author":"Gillet","year":"2013","journal-title":"JNCI J. National Cancer Instit."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0120","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jbiosc.2014.01.008","article-title":"Observation of ovarian cancer stem cell behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell culture","volume":"118","author":"Chen","year":"2014","journal-title":"J. Biosci. Bioeng."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189052_bb0555","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/labinvest.2013.41","article-title":"A three-dimensional microenvironment alters protein expression and chemosensitivity of epithelial ovarian cancer cells in vitro","volume":"93","author":"Myungjin Lee","year":"2013","journal-title":"Lab. Investig."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189052_bb0895","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/mc.20315","article-title":"Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC)","volume":"46","author":"Zietarska","year":"2007","journal-title":"Mol. Carcinog."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189052_bb0140","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00018-022-04395-y","article-title":"Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application","volume":"79","author":"Ciucci","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbcan.2023.189052_bb0330","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.actbio.2021.04.041","article-title":"Personalized models of heterogeneous 3D epithelial tumor microenvironments: ovarian cancer as a model","volume":"132","author":"Horst","year":"2021","journal-title":"Acta Biomater."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ygyno.2019.11.020","article-title":"Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer","volume":"156","author":"Collins","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0190","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13048-019-0577-2","article-title":"Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review","volume":"12","author":"Dumont","year":"2019","journal-title":"J. Ovarian Res."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189052_bb0475","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.trecan.2020.07.007","article-title":"Human-derived model Systems in Gynecological Cancer Research","volume":"6","author":"L\u00f5hmussaar","year":"2020","journal-title":"Trend. Cancer"},{"key":"10.1016\/j.bbcan.2023.189052_bb0695","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102103","article-title":"Organoid models in gynaecological oncology research","volume":"90","author":"Semertzidou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2023.189052_bb0865","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.836984","article-title":"Three-dimensional modelling of ovarian Cancer: from cell lines to organoids for discovery and personalized medicine","volume":"10","author":"Yee","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0959-8049(94)00377-H","article-title":"Radiosensitivity of multicellular tumor spheroids obtained from human ovarian cancers","volume":"31","author":"Griffon","year":"1995","journal-title":"Eur. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0320","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104013","article-title":"Stable expansion of high-grade serous ovarian cancer organoids requires a low-Wnt environment","volume":"39","author":"Hoffmann","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.bbcan.2023.189052_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2019.107421","article-title":"Extracellular matrix-derived biomaterials in engineering cell function","volume":"42","author":"Xing","year":"2020","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bbcan.2023.189052_bb0145","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.trsl.2016.03.016","article-title":"New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination","volume":"175","author":"Coffman","year":"2016","journal-title":"Transl. Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0875","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1186\/s12885-019-6470-y","article-title":"Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer","volume":"19","author":"Yue","year":"2019","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0785","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.3390\/ijms23084383","article-title":"Metastatic voyage of ovarian Cancer cells in ascites with the assistance of various cellular components","volume":"23","author":"Uno","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0870","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/1878-0261.12017","article-title":"Epithelial-mesenchymal transition in tumor metastasis","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189052_bb0760","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/jcm8101658","article-title":"Wnt signaling in ovarian Cancer Stemness, EMT, and therapy resistance","volume":"8","author":"Teeuwssen & Fodde","year":"2019","journal-title":"J. Clin. Med."},{"issue":"37","key":"10.1016\/j.bbcan.2023.189052_bb0295","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1038\/s41388-018-0317-x","article-title":"Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer","volume":"37","author":"Al Habyan","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0540","doi-asserted-by":"crossref","DOI":"10.1063\/5.0132254","article-title":"Model of collective detachment in high-grade serous ovarian cancer demonstrates that tumor spheroids produce ECM to support metastatic processes","volume":"7","author":"Micek","year":"2023","journal-title":"APL Bioeng."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0240","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1084\/jem.20180765","article-title":"Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer","volume":"216","author":"Gao","year":"2019","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0520","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10585-016-9821-y","article-title":"Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions","volume":"33","author":"Matte","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0055","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1158\/0008-5472.CAN-04-3931","article-title":"Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian Cancer","volume":"65","author":"Bapat","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0230","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2012.10.023","article-title":"Ovarian cancer stem cells: working towards the root of stemness","volume":"338","author":"Foster","year":"2013","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0715","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2008.11.032","article-title":"Multicellular spheroids in ovarian cancer metastases: biology and pathology","volume":"113","author":"Shield","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.121996","article-title":"A 3D multi-cellular tissue model of the human omentum to study the formation of ovarian cancer metastasis","volume":"294","author":"Estermann","year":"2023","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0675","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12935-022-02822-5","article-title":"The metastatic capacity of high-grade serous ovarian cancer cells changes along disease progression: inhibition by mifepristone","volume":"22","author":"Ritch","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"19","key":"10.1016\/j.bbcan.2023.189052_bb0265","doi-asserted-by":"crossref","first-page":"11782","DOI":"10.3390\/ijms231911782","article-title":"Cancer three-dimensional spheroids mimic in vivo tumor features, displaying \u201cinner\u201d extracellular vesicles and Vasculogenic mimicry","volume":"23","author":"Giusti","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2023.189052_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121728","article-title":"Omentum-on-a-chip: A multicellular, vascularized microfluidic model of the human peritoneum for the study of ovarian cancer metastases","volume":"288","author":"Ibrahim","year":"2022","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.bbcan.2023.189052_bb0020","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/cancers14122895","article-title":"A platform of patient-derived microtumors identifies individual treatment responses and therapeutic vulnerabilities in ovarian Cancer","volume":"14","author":"Anderle","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2023.189052_bb0305","doi-asserted-by":"crossref","DOI":"10.1177\/20417314221088514","article-title":"Establishment of the SIS scaffold-based 3D model of human peritoneum for studying the dissemination of ovarian cancer","volume":"13","author":"Herbert","year":"2022","journal-title":"J. Tissue Eng."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0590","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3390\/ijms23031016","article-title":"Mesothelin expression is not associated with the presence of Cancer stem cell markers SOX2 and ALDH1 in ovarian Cancer","volume":"23","author":"Nunes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0160","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3390\/cells11020237","article-title":"Wnt5A and TGF\u03b21 converges through YAP1 activity and integrin alpha v up-regulation promoting epithelial to mesenchymal transition in ovarian Cancer cells and mesothelial cell activation","volume":"11","author":"Dehghani-Ghobadi","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0795","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41418-021-00878-w","article-title":"Single cell-derived spheroids capture the self-renewing subpopulations of metastatic ovarian cancer","volume":"29","author":"Velletri","year":"2022","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bbcan.2023.189052_bb0500","doi-asserted-by":"crossref","DOI":"10.1177\/20417314211055015","article-title":"Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology","volume":"12","author":"Martinez","year":"2021","journal-title":"J. Tissue Eng."},{"issue":"16","key":"10.1016\/j.bbcan.2023.189052_bb0380","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.3390\/cancers13163931","article-title":"The natural product \u03b2-Escin targets Cancer and stromal cells of the tumor microenvironment to inhibit ovarian Cancer metastasis","volume":"13","author":"Kenny","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2023.189052_bb0630","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1038\/s41467-021-24009-8","article-title":"Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance","volume":"12","author":"Pietil\u00e4","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0745","doi-asserted-by":"crossref","DOI":"10.1088\/1758-5090\/abe1cf","article-title":"A novel tumor-immune microenvironment (TIME)-on-Chip mimics three dimensional neutrophil-tumor dynamics and neutrophil extracellular traps (NETs)-mediated collective tumor invasion","volume":"13","author":"Surendran","year":"2021","journal-title":"Biofabrication"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0660","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/cancers12082063","article-title":"Carcinoma-associated mesenchymal stem cells promote Chemoresistance in ovarian Cancer stem cells via PDGF signaling","volume":"12","author":"Raghavan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbcan.2023.189052_bb0135","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1038\/s41388-020-1264-x","article-title":"MicroRNA-200 family governs ovarian inclusion cyst formation and mode of ovarian cancer spread","volume":"39","author":"Choi","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0655","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40425-019-0666-1","article-title":"Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments","volume":"7","author":"Raghavan","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2023.189052_bb0470","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.biomaterials.2018.10.014","article-title":"A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns","volume":"190\u2013191","author":"Loessner","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0005","doi-asserted-by":"crossref","first-page":"19462","DOI":"10.1038\/s41598-020-76291-z","article-title":"Patient-derived ovarian cancer explants: preserved viability and histopathological features in long-term agitation-based cultures","volume":"10","author":"Abreu","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0450","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-022-02244-1","article-title":"Reactive oxygen species reprogram macrophages to suppress antitumor immune response through the exosomal miR-155-5p\/PD-L1 pathway","volume":"41","author":"Li","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0300","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41419-022-04976-6","article-title":"Ascitic fluid shear stress in concert with hepatocyte growth factor drive stemness and chemoresistance of ovarian cancer cells via the c-met-PI3K\/Akt-miR-199a-3p signaling pathway","volume":"13","author":"Hassan","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbcan.2023.189052_bb0115","doi-asserted-by":"crossref","first-page":"1135374","DOI":"10.3389\/fbioe.2023.1135374","article-title":"3D dynamic cultures of HGSOC organoids to model innovative and standard therapies","volume":"11","author":"Cavarzerani","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0820","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.neo.2019.06.005","article-title":"Engineered 3D model of Cancer stem cell enrichment and Chemoresistance","volume":"21","author":"Ward Rashidi","year":"2019","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0460","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3390\/ijms20040952","article-title":"High-grade serous ovarian Cancer: basic sciences, clinical and therapeutic standpoints","volume":"20","author":"Lisio","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2023.189052_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian Cancer ascites: opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0030","doi-asserted-by":"crossref","first-page":"11913","DOI":"10.1038\/s41598-020-68639-2","article-title":"Ascites-induced compression alters the peritoneal microenvironment and promotes metastatic success in ovarian cancer","volume":"10","author":"Asem","year":"2020","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189052_bb0640","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1073\/pnas.1316848111","article-title":"Mechanotransduction of fluid stresses governs 3D cell migration","volume":"111","author":"Polacheck","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.bbcan.2023.189052_bb0680","doi-asserted-by":"crossref","first-page":"e1974","DOI":"10.1073\/pnas.1216989110","article-title":"Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules","volume":"110","author":"Rizvi","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41580-018-0080-4","article-title":"New insights into the mechanisms of epithelial\u2013mesenchymal transition and implications for cancer","volume":"20","author":"Dongre","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0855","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41580-020-0237-9","article-title":"Guidelines and definitions for research on epithelial\u2013mesenchymal transition","volume":"21","author":"Yang","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12935-023-02854-5","article-title":"Tumor microenvironment in ovarian cancer peritoneal metastasis","volume":"23","author":"Mei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2023.189052_bb0405","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41416-023-02140-1","article-title":"Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT","volume":"128","author":"Kralj","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"42","key":"10.1016\/j.bbcan.2023.189052_bb0385","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1038\/onc.2017.171","article-title":"Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis","volume":"36","author":"Klymenko","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2023.189052_bb0175","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ceb.2016.06.002","article-title":"Epithelial\u2013mesenchymal transition (EMT) and metastasis: yes, no, maybe?","volume":"43","author":"Diepenbruck","year":"2016","journal-title":"Curr. Opin. Cell Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0480","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3390\/cancers11060838","article-title":"The role of epithelial-to-mesenchymal plasticity in ovarian Cancer progression and therapy resistance","volume":"11","author":"Loret","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0490","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","article-title":"The epithelial-mesenchymal transition generates cells with properties of stem cells","volume":"133","author":"Mani","year":"2008","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0605","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1186\/1471-2407-14-651","article-title":"Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumor cells from patients with early and metastatic breast cancer","volume":"14","author":"Papadaki","year":"2014","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0615","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumor progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189052_bb0705","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2023.189052_bb0050","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.tcb.2020.07.003","article-title":"EMT, MET, plasticity, and tumor metastasis","volume":"30","author":"Bakir","year":"2020","journal-title":"Trends Cell Biol."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0065","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-021-00366-w","article-title":"Cancer stem cell\u2013immune cell crosstalk in tumor progression","volume":"21","author":"Bayik","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"18","key":"10.1016\/j.bbcan.2023.189052_bb0090","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108647","article-title":"Dynamic EMT: a multi-tool for tumor progression","volume":"40","author":"Brabletz","year":"2021","journal-title":"EMBO J."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0165","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.devcel.2019.04.026","article-title":"EMT and Cancer: more than meets the eye","volume":"49","author":"Derynck","year":"2019","journal-title":"Dev. Cell"},{"key":"10.1016\/j.bbcan.2023.189052_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2020.100715","article-title":"Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance","volume":"53","author":"Erin","year":"2020","journal-title":"Drug Resist. Updat."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0335","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189052_bb0425","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00204-021-03063-7","article-title":"Cancer drug resistance induced by EMT: novel therapeutic strategies","volume":"95","author":"De Las Rivas","year":"2021","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0550","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semcancer.2021.03.038","article-title":"The hallmarks of ovarian cancer stem cells and niches: exploring their harmonious interplay in therapy resistance","volume":"77","author":"Motohara","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0860","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0650","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1530\/ERC-15-0383","article-title":"TGF\u03b2 signaling regulates epithelial\u2013mesenchymal plasticity in ovarian cancer ascites-derived spheroids","volume":"23","author":"Rafehi","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"issue":"37","key":"10.1016\/j.bbcan.2023.189052_bb0880","doi-asserted-by":"crossref","first-page":"5764","DOI":"10.1038\/sj.onc.1208927","article-title":"TGF-\u03b2 and epithelial-to-mesenchymal transitions","volume":"24","author":"Zavadil","year":"2005","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0415","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/IGC.0b013e3181bda1cb","article-title":"Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma","volume":"20","author":"Labiche","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccr.2009.12.041","article-title":"Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-\u03baB-dependent manner","volume":"17","author":"Erez","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.bbcan.2023.189052_bb0085","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0310","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0355","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","article-title":"A single-cell landscape of high-grade serous ovarian cancer","volume":"26","author":"Izar","year":"2020","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20110112","article-title":"Diverse mechanisms for activation of Wnt signalling in the ovarian tumor microenvironment","volume":"437","author":"Barbolina","year":"2011","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbcan.2023.189052_bib897","first-page":"341308","article-title":"Current concept and update of the macrophage plasticity concept: intracellular mechanisms of reprogramming and M3 macrophage \u201cSwitch\u201d phenotype","author":"Malyshev","year":"2015","journal-title":"Biomed Res Int"},{"issue":"25","key":"10.1016\/j.bbcan.2023.189052_bb0105","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1038\/onc.2014.264","article-title":"Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells","volume":"34","author":"Cai","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.bbcan.2023.189052_bib898","doi-asserted-by":"crossref","first-page":"744257","DOI":"10.3389\/fonc.2021.744257","article-title":"Ovarian biomechanics: From health to disease","volume":"11","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.bbcan.2023.189052_bb0565","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1158\/0008-5472.CAN-18-2616","article-title":"Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian Cancer metastasis","volume":"79","author":"Natarajan","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0835","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumor progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2023.189052_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00998","article-title":"Mechanisms of Vasculogenic mimicry in ovarian Cancer","volume":"9","author":"Ayala-Dom\u00ednguez","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0825","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12943-020-01288-1","article-title":"Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments","volume":"20","author":"Wei","year":"2021","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0070","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/pr.114.010215","article-title":"The great escape; the hallmarks of resistance to antiangiogenic therapy","volume":"67","author":"van Beijnum","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0455","doi-asserted-by":"crossref","first-page":"291","DOI":"10.5483\/BMBRep.2020.53.6.060","article-title":"Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer","volume":"53","author":"Lim","year":"2020","journal-title":"BMB Rep."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0710","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5483\/BMBRep.2008.41.4.278","article-title":"Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis","volume":"41","author":"Shibuya","year":"2008","journal-title":"BMB Rep."},{"issue":"17","key":"10.1016\/j.bbcan.2023.189052_bb0110","doi-asserted-by":"crossref","first-page":"5822","DOI":"10.1158\/1078-0432.CCR-11-1185","article-title":"Anti-VEGF Treatment\u2013Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype","volume":"17","author":"Carbone","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0850","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1756-9966-31-16","article-title":"Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis","volume":"31","author":"Xu","year":"2012","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.189052_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00803","article-title":"Vasculogenic mimicry: become an endothelial cell \u201cbut not so much\u201d","volume":"9","author":"Fern\u00e1ndez-Cort\u00e9s","year":"2019","journal-title":"Front. Oncol."},{"issue":"19","key":"10.1016\/j.bbcan.2023.189052_bb0220","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1158\/0008-5472.CAN-15-2630","article-title":"Acidosis acts through HSP90 in a PHD\/VHL-independent manner to promote HIF function and stem cell maintenance in glioma","volume":"76","author":"Filatova","year":"2016","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.bbcan.2023.189052_bb0510","doi-asserted-by":"crossref","first-page":"4640","DOI":"10.1158\/0008-5472.CAN-10-3320","article-title":"HIF induces human embryonic stem cell markers in Cancer cells","volume":"71","author":"Mathieu","year":"2011","journal-title":"Cancer Res."},{"issue":"39","key":"10.1016\/j.bbcan.2023.189052_bb0635","doi-asserted-by":"crossref","first-page":"16805","DOI":"10.1073\/pnas.0904606106","article-title":"HIF-2\u03b1 maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells","volume":"106","author":"Pietras","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0130","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2174\/156720211796558023","article-title":"CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo","volume":"8","author":"Chiao","year":"2011","journal-title":"Curr. Neurovasc. Res."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0435","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000445747","article-title":"Association of Vasculogenic Mimicry Formation and CD133 expression with poor prognosis in ovarian Cancer","volume":"81","author":"Liang","year":"2016","journal-title":"Gynecol. Obstet. Investig."},{"issue":"20","key":"10.1016\/j.bbcan.2023.189052_bb0805","doi-asserted-by":"crossref","first-page":"29051","DOI":"10.18632\/oncotarget.8665","article-title":"CD133+ cancer stem-like cells promote migration and invasion of salivary adenoid cystic carcinoma by inducing vasculogenic mimicry formation","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2023.189052_bb0790","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00680","article-title":"Fact or fiction, it is time for a verdict on Vasculogenic mimicry?","volume":"9","author":"Valdivia","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0250","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.2147\/CMAR.S164675","article-title":"Overview of advances in vasculogenic mimicry - a potential target for tumor therapy","volume":"10","author":"Ge","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.bbcan.2023.189052_bib899","first-page":"2514","article-title":"A three-dimensional culture-based assay to detect early stages of vasculogenic mimicry in ovarian cancer cells","author":"Salinas-Vera","year":"2022","journal-title":"Methods Mol Biol"},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0690","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/path.4889","article-title":"Mesothelial-to-mesenchymal transition as a possible therapeutic target in peritoneal metastasis of ovarian cancer","volume":"242","author":"Rynne-Vidal","year":"2017","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0515","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/1471-2407-14-288","article-title":"Role of malignant ascites on human mesothelial cells and their gene expression profiles","volume":"14","author":"Matte","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0735","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-019-0970-x","article-title":"Therapy resistance mediated by exosomes","volume":"18","author":"Steinbichler","year":"2019","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0775","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41419-022-04510-8","article-title":"Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion","volume":"13","author":"Tian","year":"2022","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.6004\/jnccn.2021.0007","article-title":"Ovarian Cancer, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"19","author":"Armstrong","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189052_bb0885","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2023.189052_bb0370","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and its evolving role in the Management of Ovarian Cancer","volume":"2015","author":"Kampan","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.bbcan.2023.189052_bb0235","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","article-title":"New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy","volume":"29","author":"Gabizon","year":"2016","journal-title":"Drug Resist. Updat."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189052_bb0400","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor Rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0625","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2023.189052_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"22","key":"10.1016\/j.bbcan.2023.189052_bb0770","doi-asserted-by":"crossref","first-page":"6581","DOI":"10.1158\/1078-0432.CCR-19-1089","article-title":"Targeting topoisomerase I in the era of precision medicine","volume":"25","author":"Thomas & Pommier","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.189052_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156234","article-title":"Etoposide: a rider on the cytokine storm","volume":"168","author":"Bailly","year":"2023","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bib900","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ygyno.2019.09.026","article-title":"Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis","volume":"155","author":"Berg","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0170","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12935-022-02624-9","article-title":"Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine","volume":"22","author":"Dhyani","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2023.189052_bb0530","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2020.08.013","article-title":"New approaches for targeting platinum-resistant ovarian cancer","volume":"77","author":"McMullen","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0600","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cac2.12138","article-title":"EMT-associated microRNAs and their roles in cancer stemness and drug resistance","volume":"41","author":"Pan","year":"2021","journal-title":"Cancer Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2023.189052_bb0465","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.drudis.2020.04.015","article-title":"Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer","volume":"25","author":"Liu","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbcan.2023.189052_bb0495","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","article-title":"Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments","volume":"77","author":"Marchetti","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0595","first-page":"304","article-title":"Mechanisms of chemotherapy resistance in ovarian cancer","volume":"5","author":"Ortiz","year":"2022","journal-title":"Cancer Drug Resistan."},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0390","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1073\/pnas.90.8.3294","article-title":"Acquired multicellular-mediated resistance to alkylating agents in cancer","volume":"90","author":"Kobayashi","year":"1993","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0750","first-page":"87","article-title":"Radiation response of multicell spheroids--an in vitro tumor model","volume":"11","author":"Sutherland","year":"1976","journal-title":"Curr. Top. Radiat. Res. Q."},{"key":"10.1016\/j.bbcan.2023.189052_bb0670","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13046-017-0570-9","article-title":"Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids","volume":"36","author":"Riffle","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0585","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/bit.26845","article-title":"3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs","volume":"116","author":"Nunes","year":"2019","journal-title":"Biotechnol. Bioeng."},{"issue":"15","key":"10.1016\/j.bbcan.2023.189052_bb0315","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1158\/0008-5472.CAN-17-3993","article-title":"Licofelone enhances the efficacy of paclitaxel in ovarian Cancer by reversing drug resistance and tumor stem-like properties","volume":"78","author":"Hirst","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2023.189052_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114458","article-title":"Autophagy in cancer resistance to paclitaxel: development of combination strategies","volume":"161","author":"\u0160kubn\u00edk","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0810","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2018.04.557","article-title":"Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer","volume":"150","author":"Wang","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0420","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13048-020-00660-5","article-title":"Activated CAMKK\u03b2-AMPK signaling promotes autophagy in a spheroid model of ovarian tumor metastasis","volume":"13","author":"Laski","year":"2020","journal-title":"J. Ovarian Res."},{"issue":"28","key":"10.1016\/j.bbcan.2023.189052_bb0185","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1038\/s41388-018-0189-0","article-title":"Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3\/Rab proteins","volume":"37","author":"Dorayappan","year":"2018","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0830","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth ovarian Cancer consensus conference of the gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0155","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ygyno.2021.08.001","article-title":"Platinum resistance in gynecologic malignancies: response, disease free and overall survival are predicted by biochemical signature: a metabolomic analysis","volume":"163","author":"D\u2019Amora","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0015","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41698-022-00298-0","article-title":"Targeting Mre11 overcomes platinum resistance and induces synthetic lethality in XRCC1 deficient epithelial ovarian cancers","volume":"6","author":"Alblihy","year":"2022","journal-title":"Precis. Oncol."},{"issue":"9","key":"10.1016\/j.bbcan.2023.189052_bb0325","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3390\/cancers14092279","article-title":"Interpatient heterogeneity in drug response and protein biomarker expression of recurrent ovarian Cancer","volume":"14","author":"Hoffman","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0580","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.3390\/ijms23063036","article-title":"Effect of ALDH1A1 gene knockout on drug resistance in paclitaxel and Topotecan resistant human ovarian Cancer cell lines in 2D and 3D model","volume":"23","author":"Nowacka","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0610","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3390\/cancers14040958","article-title":"Patient-derived ovarian Cancer spheroids rely on PI3K-AKT signaling addiction for Cancer Stemness and Chemoresistance","volume":"14","author":"Parashar","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0730","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3892\/ijo.2022.5325","article-title":"Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers","volume":"60","author":"Singh","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0215","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ygyno.2022.01.008","article-title":"Dubious effects of methadone as an \u201canticancer\u201d drug on ovarian cancer cell-lines and patient-derived tumor-spheroids","volume":"165","author":"Fiegl","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189052_bb0080","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.3390\/biom11111711","article-title":"Epigenetic therapy augments classic chemotherapy in suppressing the growth of 3D high-grade serous ovarian Cancer spheroids over an extended period of time","volume":"11","author":"Bilbao","year":"2021","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0100","doi-asserted-by":"crossref","first-page":"18183","DOI":"10.1038\/s41598-021-97434-w","article-title":"Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models","volume":"11","author":"Brodeur","year":"2021","journal-title":"Sci. Rep."},{"issue":"12","key":"10.1016\/j.bbcan.2023.189052_bb0620","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244549","article-title":"Carboplatin sensitivity in epithelial ovarian cancer cell lines: the impact of model systems","volume":"15","author":"Patra","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0720","doi-asserted-by":"crossref","first-page":"11153","DOI":"10.1038\/s41598-019-47578-7","article-title":"Prospective validation of an ex vivo, patient-derived 3D spheroid model for response predictions in newly diagnosed ovarian Cancer","volume":"9","author":"Shuford","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0350","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1007\/s13577-022-00827-w","article-title":"Ex vivo chemosensitivity assay using primary ovarian cancer organoids for predicting clinical response and screening effective drugs","volume":"36","author":"Ito","year":"2023","journal-title":"Hum. Cell"},{"issue":"8","key":"10.1016\/j.bbcan.2023.189052_bb0270","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3390\/biomedicines9081021","article-title":"Utilizing patient-derived epithelial ovarian Cancer tumor organoids to predict carboplatin resistance","volume":"9","author":"Gorski","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0560","doi-asserted-by":"crossref","first-page":"12581","DOI":"10.1038\/s41598-020-69488-9","article-title":"Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumors applicable for drug sensitivity and resistance testing","volume":"10","author":"Nanki","year":"2020","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189052_bib896","doi-asserted-by":"crossref","first-page":"107762","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.bbcan.2023.189052_bb0125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.ygyno.2020.03.026","article-title":"Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma","volume":"157","author":"Chen","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0285","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ygyno.2020.09.002","article-title":"The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration","volume":"59","author":"Gunay","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189052_bb0815","doi-asserted-by":"crossref","first-page":"11042","DOI":"10.18632\/aging.103317","article-title":"Highly expressed STAT1 contributes to the suppression of stemness properties in human paclitaxel-resistant ovarian cancer cells","volume":"12","author":"Wang","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0375","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13046-021-02086-3","article-title":"Chemoresistance is mediated by ovarian cancer leader cells in vitro","volume":"40","author":"Karimnia","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2023.189052_bb0800","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.83867","article-title":"High-grade serous ovarian carcinoma organoids as models of chromosomal instability","volume":"12","author":"Vias","year":"2023","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.bbcan.2023.189052_bb0700","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12967-020-02613-4","article-title":"Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy","volume":"18","author":"Sheta","year":"2020","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2023.189052_bb0890","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/s41416-020-0825-7","article-title":"Chemotherapy exacerbates ovarian cancer cell migration and cancer stem cell-like characteristics through GLI1","volume":"122","author":"Zhao","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.bbcan.2023.189052_bb0075","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3390\/cancers11091228","article-title":"Keratin-14 (KRT14) positive leader cells mediate mesothelial clearance and invasion by ovarian Cancer cells","volume":"11","author":"Bilandzic","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0545","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.3390\/ijms20061466","article-title":"Therapeutic targeting of collective invasion in ovarian Cancer","volume":"20","author":"Moffitt","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2023.189052_bib901","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211039899","article-title":"Immune checkpoint inhibitors in ovarian cancer: where do we stand?","volume":"13","author":"Leary","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bbcan.2023.189052_bib902","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"10.1016\/j.bbcan.2023.189052_bib903","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/1078-0432.CCR-21-3844","article-title":"FDA approval summary: pembrolizumab, atezolizumab, and cemiplimab-rwlc as single agents for first-line treatment of advanced\/metastatic PD-L1-high NSCLC","volume":"28","author":"Akinboro","year":"2022","journal-title":"Clin Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2023.189052_bb0290","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.3390\/cancers14051274","article-title":"A systematic comparative assessment of the response of ovarian Cancer cells to the chemotherapeutic cisplatin in 3D models of various structural and biochemical configurations\u2014does one model type fit all?","volume":"14","author":"Gupta","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2023.189052_bb0725","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1039\/C8LC00982A","article-title":"Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex-vivo solid tumors","volume":"19","author":"Simeone","year":"2019","journal-title":"Lab Chip"},{"issue":"9","key":"10.1016\/j.bbcan.2023.189052_bb0275","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s12094-014-1192-8","article-title":"Overview of a chemoresponse assay in ovarian cancer","volume":"16","author":"Grendys","year":"2014","journal-title":"Clin. Transl. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2023.189052_bb0685","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2013.08.009","article-title":"A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer","volume":"131","author":"Rutherford","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.bbcan.2023.189052_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111536","article-title":"Drug resistance evaluation in novel 3D in vitro model","volume":"138","author":"Nowacka","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.bbcan.2023.189052_bb0360","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.biopha.2014.02.002","article-title":"Drug transporter expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line","volume":"68","author":"Januchowski","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"30","key":"10.1016\/j.bbcan.2023.189052_bb0365","doi-asserted-by":"crossref","first-page":"49944","DOI":"10.18632\/oncotarget.18278","article-title":"Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines","volume":"8","author":"Januchowski","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2023.189052_bb0045","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2023.189052_bb0485","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.devcel.2021.07.009","article-title":"Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies","volume":"56","author":"Lukow","year":"2021","journal-title":"Dev. Cell"},{"issue":"11","key":"10.1016\/j.bbcan.2023.189052_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian Cancer organoids mimic clinical response and exhibit heterogeneous inter- and Intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbcan.2023.189052_bb0255","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s12079-022-00698-8","article-title":"Friend and foe: the regulation network of ascites components in ovarian cancer progression","volume":"17","author":"Geng","year":"2022","journal-title":"J. Cell Communicat. Signal."},{"issue":"6","key":"10.1016\/j.bbcan.2023.189052_bb0765","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","article-title":"Patient-derived tumor xenografts as models for oncology drug development","volume":"9","author":"Tentler","year":"2012","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23002019?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X23002019?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:50:00Z","timestamp":1759639800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X23002019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0304419X23002019"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.189052","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The high-grade serous ovarian cancer metastasis and chemoresistance in 3D models","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2023.189052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"189052"}}